HER2-positive biliary tract cancer (BTC), including unresectable locally advanced or metastatic disease research hub

Real-world outcomes of patients with HER2-positive biliary tract cancer treated with zanidatamab through an Early Access Programme

This study looks at medical records of adults who received a cancer medicine called zanidatamab through an Early Access Programme. Researchers want to see how well the drug worked in real-world care for advanced HER2-positive bile duct cancer. Taking part involves no new medicines, tests, or hospital visits.